" class="no-js "lang="en-US"> Sage Therapeutics Appoints Jessica Federer to Board of Directors
Friday, June 14, 2024

Sage Therapeutics Appoints Jessica Federer to Board of Directors

Sage Therapeutics, a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company’s Board of Directors.

“We are thrilled to have Jessica join our Board of Directors. Jessica is a champion for patients and has a track record of innovation in data and digital transformation which will be a key future growth driver for the industry,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “Jessica’s innate curiosity, commitment to challenging convention, and patient-first mindset are consistent with the critical values that define our leaders. Her unique expertise in data and digitalization at the intersection of policy and science will help us continue to scale our commercial growth ambitions.”

Ms. Federer is a managing partner at Supernode Ventures where she is working to address a critical gap in innovation by accelerating change through investment in women’s health and health technology companies as early as possible in pre-seed, seed, and Series A rounds. She was the first Chief Digital Officer for the Bayer AG group, as well as the first woman to hold that role in the industry. During her tenure, Ms. Federer united the company’s global digital strategy and investments to accelerate growth. She also held leadership positions in regulatory affairs, market access, communications, and public affairs during her almost 10 years with Bayer AG.

Ms. Federer has served on the United Nations International Telecommunications Union (UN-ITU) advisory board, as well as participated in engagements with the World Economic Forum, and is considered a thought leader in digital health. She began her public health career as an analyst at the Agency for Healthcare Research and Quality in the U.S. Department of Health and Human Services. She earned a Bachelor of Science from the George Washington University and a Master of Public Health from Yale University.

“I’m honored to join the Sage Board of Directors at such an incredibly exciting time. Sage has led the way in maternal mental health care, an area of great need and one that is particularly important to me. I’m looking forward to supporting the company’s goal of redefining how we think about and treat a wide range of brain health conditions. I see the vast potential for data and digital strategies in the brain health area,” said Ms. Federer.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more